Kevin Tan Net Worth

The estimated Net Worth of Kevin Tan is at least $11.7 Tisíc dollars as of 9 January 2024. Mr Tan owns over 11,250 units of Selecta Biosciences Inc stock worth over $11,654 and over the last 3 years he sold SELB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Tan SELB stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Selecta Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 11,250 units of SELB stock worth $9,900 on 9 January 2024.

The largest trade he's ever made was exercising 11,250 units of Selecta Biosciences Inc stock on 9 January 2024 worth over $9,900. On average, Mr trades about 2,708 units every 128 days since 2021. As of 9 January 2024 he still owns at least 13,243 units of Selecta Biosciences Inc stock.

You can see the complete history of Mr Tan stock trades at the bottom of the page.

Mr. Kevin Tan biography

Kevin Tan is the Chief Financial Officer at Selecta Biosciences Inc.

How old is Mr Tan?

Mr Tan is 44, he's been the Chief Financial Officer of Selecta Biosciences Inc since . There are 14 older and 2 younger executives at Selecta Biosciences Inc. The oldest executive at Selecta Biosciences Inc is Patrick Zenner, 73, who is the Independent Director.

What's Mr Tan's mailing address?

Kevin's mailing address filed with the SEC is 65, Grove Street, Rangely Acres, Waltham, Middlesex County, Massachusetts, 02452-6272, United States.

Insiders trading at Selecta Biosciences Inc

Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit... a Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.

What does Selecta Biosciences Inc do?

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat

Complete history of Mr Tan stock trades at Selecta Biosciences Inc a Solid Biosciences Inc

Selecta Biosciences Inc executives and stock owners

Selecta Biosciences Inc executives and other stock owners filed with the SEC include:

• Carsten Brunn,
  President, Chief Executive Officer, Director
• Lloyd Johnston,
  Chief Operating Officer, Senior Vice President - Research & development
• Dr. Carsten Brunn,
  CEO, Pres & Director
• Dr. Peter G. Traber M.D.,
  Chief Medical Officer
• Patrick Zenner,
  Independent Director
• Timothy Springer,
  Independent Director
• Timothy Barabe,
  Independent Director
• Aymeric Sallin,
  Independent Director
• Scott Myers,
  Independent Director
• Carrie Cox,
  Independent Chairman of the Board
• Lee Stern,
  IR Contact Officer
• Goran Ando,
  Independent Director
• Bradford Dahms,
  Chief Financial Officer, Principal Accounting Officer
• Takashi Kishimoto,
  Chief Scientific Officer
• Kristen Baldwin,
  Chief People Officer
• Dr. Takashi Kei Kishimoto Ph.D.,
  Chief Scientific Officer
• Dr. Lloyd Johnston,
  COO and Sr. VP of R&D
• Kevin Tan,
  Chief Financial Officer
• Ann K. Donohue,
  VP of Fin., Interim Principal Financial Officer & Principal Accounting Officer
• Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D.,
  Co-Founder and Co-Chair of the Scientific Advisory Board
• Omid Farokhzad,
  Director
• Peter Barton Hutt,
  Director
• Edwin M Jr Kania,
  Director
• Peter Keller,
  Chief Business Officer
• Advisors Llc Orbi Med Capit...,
  
• Rusnano,
  10% owner
• Carl L Gordon,
  Director
• Capital I2 Bf Netherlands, ...,
  
• University Partners Ii, L.P...,
  
• Management Ltd Nanodimensio...,
  
• Partners, Llc Leukon Invest...,
  
• Venture Management Co. V, L...,
  
• Ventures Fund 2007, L.P.Fla...,
  
• Earl Sands,
  Chief Medical Officer
• David Siewers,
  Chief Financial Officer
• David Abraham,
  CCO, GC and Corp. Sec.
• Nishan M De Silva,
  Director
• Werner Cautreels,
  President and CEO
• Amir Nashat,
  Director
• John Harold Leaman,
  CFO, Treas. & Hd Corp Strategy
• Stephen Smolinski,
  Chief Commercial Officer
• Elona Kogan,
  General Counsel
• Peter G Traber,
  Chief Medical Officer
• Alison D. Schecter,
  Chief Medical Officer
• Kevin Tan,
  Chief Financial Officer
• Blaine Davis,
  Chief Financial Officer